Clinical trials: Obstructive Coronary Artery Disease
Non-obstructive Coronary Disease, Acute or Chronic Coronary Artery Disease
Simultaneous Measurement of EpicArdial and Microvascular ResisTance Via Angiographic FLOW Study
The aim of this study is to establish the diagnostic performance of the AngioAI+ System (AngioInsight, Inc, USA) for estimating: 1. Fractional flow reserve (FFR) and 2.
- Trial name
- SMARTFLOW (NCT07676097)
- Testing
- Patients with intermediate coronary artery stenosis with clinically indicated FFR assessment., Microvascular assessment
- Where
- 9 sites in United States
- Volunteers
- 620 people
- Sponsor
- AngioInsight
Coronary Microvascular Dysfunction, Coronary Microvascular Disease
A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction
This clinical trial will explore the efficacy and safety of GCSF-mobilized autologous CD34+ cells for the treatment of CMD in adults currently experiencing angina and with no obstructive coronary artery disease.
- Conditions
- Coronary Microvascular Dysfunction, Coronary Microvascular Disease, Microvascular Coronary Artery Disease
- Trial name
- FREEDOM (NCT04614467)
- Testing
- CLBS16
- Where
- 7 sites in United States
- Volunteers
- 34 people
- Sponsor
- Lisata Therapeutics, Inc.
Ischemia With Non-Obstructive Coronary Artery, Angina Pectoris
Efficacy and Safety of Shexiang Baoxin Pill in Patients With Ischemia With Non-Obstructive Coronary Artery
This is a multicenter, randomized, double-blind, placebo-controlled clinical trial. Patients were treated with the trial drug or placebo in a 1:1 ratio.
- Conditions
- Ischemia With Non-Obstructive Coronary Artery, Angina Pectoris, Coronary Heart Disease, X Syndrome, Angina
- Trial name
- LESS (NCT04897126)
- Testing
- Shexiang Baoxin pill（MUSKARDIA）
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Shanghai Hutchison Pharmaceuticals Limited
Coronary Microvascular Dysfunction
Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease
This clinical trial will explore the safety and effect of GCSF-mobilized autologous ex vivo selected CD34 cells for the treatment of CMD in adults currently experiencing angina and with no obstructive coronary artery disease.
- Trial name
- NCT03508609
- Testing
- CLBS16
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Lisata Therapeutics, Inc.
Primary Prevention of Atherosclerotic Cardiovascular Disease
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at…
- Trial name
- NCT05739383
- Testing
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Where
- 983 sites in United States, Argentina and 40 more
- Volunteers
- 14,012 people
- Sponsor
- Novartis Pharmaceuticals
Ischemic Heart Disease, Coronary Microvascular Disease
MCG for Suspected INOCA Confirmed by Thermodilution-Derived CFR
This study will be an observational registry to investigate the ability of magnetocardiography (MCG) in determining the presence of myocardial ischemia with the absence of obstructive coronary artery disease, by using an invasive…
- Conditions
- Ischemic Heart Disease, Coronary Microvascular Disease, Angina
- Trial name
- MICRO(T) (NCT06139094)
- Testing
- CardioFlux Magnetocardiography
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Genetesis Inc.
Ischemic Heart Disease, Coronary Microvascular Disease
MCG as a Noninvasive Diagnostic Strategy for Suspected INOCA (MICRO2)
A prospective, multicenter, observational, single-arm trial to validate CardioFlux MCG's ability to diagnose myocardial ischemia caused by coronary microvascular dysfunction in patients with suspected ischemia and confirmed no…
- Conditions
- Ischemic Heart Disease, Coronary Microvascular Disease, Angina, Myocardial Ischemia
- Trial name
- MICRO2 (NCT06212466)
- Testing
- CardioFlux
- Where
- 8 sites in United States
- Volunteers
- 136 people
- Sponsor
- Genetesis Inc.
Coronary Artery Disease
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
CKJX839D12303 is a research study to determine if the study treatment, called inclisiran, in comparison to placebo taken in addition to statin medication can effectively reduce the total amount of plaque formed in the heart's…
- Trial name
- V-PLAQUE (NCT05360446)
- Testing
- Inclisiran sodium 300 mg
- Where
- 89 sites in United States, Argentina and 16 more
- Volunteers
- 610 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Hypertension
Dose Determination Safety and Activity Study of Inhaled NX1011 to Treat Pulmonary Arterial Hypertension
The purpose of this study is to determine the safety and maximum tolerated dose of inhaled NX1011 for the treatment of pulmonary arterial hypertension (PAH).
- Trial name
- NCT00323024
- Testing
- NX1011
- Where
- 6 sites in United States
- Volunteers
- 72 people
- Sponsor
- NITROX, LLC
Coronary Artery Disease
Safety and Efficacy Study of PB127 Ultrasound Contrast Agent in Patients With Suspected Coronary Artery Disease
This trial is to compare PB127 echocardiography to other heart imaging studies.
- Trial name
- NCT00595244
- Testing
- PB127 for injectable suspension
- Where
- 15 sites in United States
- Volunteers
- 456 people
- Sponsor
- Point Biomedical
Coronary Artery Disease, Chest Pain
Coronary Obstruction Detection by Molecular Personalized Gene Expression (Corus CAD or ASGES)
To validate the use of Corus CAD (Age/Sex/Gene Expression score - ASGES) blood assay in subjects who are referred for the work-up of coronary artery disease.
- Conditions
- Coronary Artery Disease, Chest Pain, Cardiovascular Diseases, Coronary Heart Disease
- Trial name
- COMPASS (NCT01117506)
- Testing
- Corus CAD (ASGES)
- Where
- 7 sites in United States
- Volunteers
- 581 people
- Sponsor
- CardioDx
Coronary Atherosclerosis
Endothelial Function-guided Therapy Compared to Usual Care in Patients With NOCAD
The current study is designed to test the hypothesis that compared to conventional treatment; endothelial function-guided treatment reduces adverse cardiovascular events in patients with non-obstructive coronary artery disease…
- Trial name
- EndoGET (NCT02313987)
- Where
- 2 sites in Israel
- Sponsor
- Itamar-Medical, Israel